摘要
目的:分析有机阴离子转运体1B1(SLCO1B1)与载脂蛋白E(ApoE)基因多态性分布及其对瑞舒伐他汀使用风险的评估价值。方法:选取2017年4月至2020年2月,我院心血管内科收治的高脂血症患者108例,均口服瑞舒伐他汀钙片10 mg/次,1次/d,睡前服用。采用纳米磁珠法提取全血基因组DNA,应用聚合酶链反应(PCR)-焦磷酸测序法测定SLCO1B1与ApoE基因多态性,比较不同SL-CO1B1基因型、不同ApoE基因型患者服药前后TC、TG、HDL-C、LDL-C水平和不良反应发生率。结果:SLCO1B1(521T>C)基因型分布为TT 73.15%、TC 23.15%、CC 3.70%;ApoE基因型分布为ε3/ε364.81%、ε2/ε312.96%、ε3/ε417.59%、ε4/ε44.64%,未见ε2/ε2、ε2/ε4基因型;服药6周后,TC型、CC型TC、LDL-C水平低于TT型,TC型、CC型HDL-C高于TT型(P<0.05),三种基因型患者TG比较,差异无统计学意义(P>0.05);ApoE基因型中,ε3/ε3型服药后TC、LDL-C高于其他基因型(P<0.05),四种基因型TG、HDL-C比较,差异无统计学意义(P>0.05);TC型、CC型肌痛发生率高于TT型,ε2/ε3型头痛、恶心、腹痛、瘙痒发生率高于其他基因型(P<0.05)。结论:SLCO1B1、ApoE基因多态性分布与瑞舒伐他汀疗效和安全性有一定关联,检测SLCO1B1与ApoE基因型有助于进行疗效预测和风险评估,实现个体化给药。
Objective:To analyze the polymorphism distribution of solute carrier organic anion transporter family member 1B1(SLCO1B1)and apolipoprotein E(ApoE)genes and the value in risk assessment of using rosuvastatin.Methods:108 patients with hyperlipidemia treated in Internal Medicine-Cardiovascular De-partment of the hospital between April 2017 and February 2020 were enrolled in the study.All of them orally took rosuvastatin calcium tablets 10 mg/time,once/day before bedtime.The whole blood genomic DNA was extracted by nano-magnetic beads method,and the SLCO1B1 and ApoE gene polymorphism was determined by polymerase chain reaction(PCR)-pyrophosphate sequencing method.The TC,TG,HDL-C,LDL-C levels and the incidence of adverse reactions in patients with different SLCO1B1 genotypes and different ApoE geno-types were compared.Results:SLCO1B1(521T>C)genotype distribution was TT 73.15%,TC 23.15%and CC 3.70%.ApoE genotype distribution wasε3/ε364.81%,ε2/ε312.96%,ε3/ε417.59%,ε4/ε44.64%,noε2/ε2 orε2/ε4 genotype.After 6 weeks of medication,TC and LDL-C levels in patients with TC type and CC type were lower than those with TT type,while HDL-C levels were higher than TT type(P<0.05).There was no statistically significant difference in TG among the three genotypes(P>0.05).Among the ApoE genotypes,TC and LDL-C in patients withε3/ε3 were higher than other genotypes after medication(P<0.05).There was no statistically significant difference in TG or HDL-C among the four genotypes(P>0.05).The incidence rates of myalgia in patients with TC type and CC type were higher than TT type.The incidence rates of headache,nausea,abdominal pain and itching in patients with ε2/ε3 type were higher than other genotypes(P<0.05).Conclusions:The SLCO1B1 and ApoE gene polymorphism distribution is related to the curative effect and safety of rosuvastatin.The detection of SLCO1B1 and ApoE genotypes can help efficacy prediction and risk assessment,realizing individualized administration.
作者
贺红祥
李贵民
张文魁
梁俊梅
尚靖智
HE Hongxiang;LI Guimin;ZHANG Wenkui;LIANG Junmei;SHANG Jingzhi(Department of Cardiovascular Medicine,Qingyang People’s Hospital,Qingyang 745000,China)
出处
《心肺血管病杂志》
2020年第11期1346-1350,共5页
Journal of Cardiovascular and Pulmonary Diseases
基金
甘肃省科技计划项目(20JR5RM627)。
关键词
有机阴离子转运体1B1
载脂蛋白E
基因多态性
瑞舒伐他汀
风险
Solute carrier organic anion transporter family member 1B1
Apolipoprotein E
Gene poly-morphism
Rosuvastatin
Risk
